Cynvenio’s Chief Medical Officer, Paul Y. Song, M.D., to Present at Liquid Biopsies and Minimally-Invasive Diagnostics 2017

August 31, 2017 – Paul Y. Song, M.D., Cynvenio Chief Medical Officer, will deliver a presentation, titled “The Role of Liquid Biopsies in Immunotherapy Selection and Monitoring” at the Select Biosciences Liquid Biopsies and Minimally-Invasive Diagnostics 2017 Conference in San Diego, California.

Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy

August 17, 2017 – Cynvenio Biosystems, Inc. announces the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.

Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression 
in Lung Cancer

August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.

Cynvenio Announces New Deployment of LiquidBiopsy® System at
 Leading Cancer Research Center in South Korea

July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.

Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois

June 1, 2017 – Cynvenio's LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published. 

Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients

May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.

Cynvenio Announces ClearID Total Insight, a New Comprehensive LiquidBiopsy Monitoring Program for Breast Cancer

March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.

Cynvenio and Color Partner to Offer Comprehensive Hereditary and Somatic Cancer Testing from Simple Blood Draw

February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.